An Open-label, Randomized, in Parallel Groups Comparative Study of Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Omalizumab (JSC "GENERIUM", Russia) and Xolair® ("Novartis Pharma AG", Switzerland) After Single-dose Subcutaneous Administration in Healthy Volunteers at 150 mg
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors GENERIUM Pharmaceuticals
- 28 Oct 2020 New trial record